Arie Belldegrun

Arie S. Belldegrun (born 1949), FACS, is an Israeli-born American urologic oncologist, businessman, and investor.

Arie S. Belldegrun
Born1949 (age 70–71)
Israel
CitizenshipIsraeli and American
Alma materHadassah Medical Center
Weizmann Institute of Science
Years active1988–present
Known forFounder of Kite Pharma
Net worth US$1.3 billion (2020)
Spouse(s)Rebecka Belldegrun
Children4
RelativesPoju Zabludowicz (brother-in-law)
Anita Zabludowicz (sister-in-law)

Early life and education

Belldegrun was born in Israel.[1] He received his medical degree from the Hadassah Medical Center at Hebrew University of Jerusalem in 1974, and conducted his post-graduate studies at the Weizmann Institute of Science in 1979.[2] He completed his urologic surgery residency at Harvard Medical School in 1985, and his Surgical Oncology fellowship at the National Cancer Institute in 1988.[2] He is certified by the American Board of Urology, and is a fellow of the American College of Surgeons and the American Association of Genitourinary Surgeons.[3][4] Belldegrun is the director of the UCLA Institute of Urologic Oncology, professor of urology, and chief of the Division of Urologic Oncology at the David Geffen School of Medicine.[5][6][7]

Career

In 1996, Belldegrun established his first company, Agensys, which was an early-stage privately-held biotechnology company based in Los Angeles. The company was focused on the development of fully human monoclonal antibodies to treat solid tumor cancers in a variety of cancer targets. He served as its founding chairman of the board of directors from 1996 to 2002, and then as a director.

In 2003, Belldegrun became the founding vice-chairman of the board of directors and chairman of the scientific advisory board of Cougar Biotechnology; the company had a focus in the field of oncology. In December 2007, Agensys was acquired by Astellas Pharma in a deal valued at $537 million.[8][9]

In 2008, Belldegrun became the chairman and partner of Two River, a New York-based venture capital firm and merchant bank focused on the life science sector. Two River specializes in investments in life science, biotechnology, and in firms focused on developing preventative and therapeutic technologies for a broad spectrum of disease areas including oncology, cardiovascular disease, neurological disorders, and companion animal health care.[10]

In July 2009, Cougar Biotechnology was acquired by Johnson & Johnson in a $970 million transaction. In April 2011, the United States Food and Drug Administration approved abiraterone acetate (Zytiga), Cougar's lead product, for late-stage prostate cancer.[11][12] Belldegrun is the founder, chairman, president and CEO of Kite Pharma. Although founded in 2009, the company went public in June 2014. Based in Santa Monica, Kite Pharma is a commercial-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products with a primary focus on engineered autologous T cell therapy (eACT) designed to restore the immune system's ability to recognize and eradicate tumors.[13] On August 28, 2017, Gilead Sciences announced that it would acquire Kite Pharma for $11.9 billion in an all-cash deal,[14] equating to $180 cash per share. The deal added CAR-T candidate to Gilead's existing portfolio.[15] The acquisition was completed in October 2017.[16] In October 2017, Kite Pharma's therapy, Yescarta (axicabtagene ciloleucel) became the first CAR-T therapy approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.[17]

In 2017, Belldegrun became the co-founder and senior managing director of Vida Ventures, a Boston-based life sciences investment firm that consists of scientists, physicians, entrepreneurs, and investors passionate about building and funding breakthroughs in biomedicine. Vida Ventures has a bicoastal presence and as of April 2018 has approximately $295 million in assets under management. Some of the companies in its portfolio include Allogene Therapeutics, Kronos Bio, A2 Biotherapeutics, AskBio, Homology Medicines, Kadiant, Oyster Point Pharma, Peloton Therapeutics, Praxis Precision Medicines, Precision Medicine Group, Pionyr Immunotherapeutics and Sutro Biopharma.[18][19][20][21][22] In 2017, Belldegrun also co-founded Allogene Therapeutics (NASDAQ: ALLO), a San Francisco-based biotechnology company. Allogene has raised $300 in Series A fundraising, and $120 million in a private financing round.[23][24][25][26] On October 11, 2018, Allogene Therapeutics raised $324 million in an initial public offering on the NASDAQ, listing under the ticker "ALLO".[27][28]

In July 2019, it was reported that Bellco Capital, Belldegrun's family office, has entered into a joint venture with Tishman Speyer to start Breakthrough Properties. Belldegrun's son, Dan, is the company's CEO. The company purchased its first property in Boston's Seaport District for $80 million.[29][30] In August 2019, Vida Ventures closed its second fund (Vida Ventures II) with $600 million. Vida Ventures currently has approximately $1 billion in assets under management.[31]

Personal life

Belldegrun is married to Rebecka Belldegrun and together they have four children.[32] They reside in Bel Air, Los Angeles.[33]

In 2014, according to the Bloomberg Pay Index, Belldegrun was ranked the 8th highest-paid executive in the United States, with a pay package valued at $95.2 million.[34] In 2015, The Hollywood Reporter's annual Hollywood's Top Doctors list included Belldegrun as one of the highest-rated urologists.[35]

In 2020, in its annual ranking of the wealthiest people in Israel, TheMarker ranked Arie and Rebecka Belldegrun 49th with a personal net worth of $1.3 billion.[36] In 2012, they have donated over $1 million to the University of Pennsylvania School of Arts and Sciences,[37] and have donated a $5 million sculpture to LACMA.[38][39]

Belldegrun was featured in the 2017-2020 editions of the LA500-LA's Most Influential People, compiled by the Los Angeles Business Journal,[40][41][42][43] and has been named Business Leader of the Year for 2018 in the Health Care category for a life dedicated to finding cures for cancer.[44] He was also featured in the CEO Today USA Awards 2017 which celebrate the success, innovation and strategic vision of CEOs across a number of sectors, industries within the US, identifying the most successful, innovative and forward-thinking CEOs in business today.[45] In June 2018, Belldegrun received the EY Master Entrepreneur Award at the Entrepreneur of the Year 2018 Awards.[46]

Belldegrun has written over 500 scientific publications related to urologic oncology and has authored several books on prostate and kidney cancers.[47][48] He was one of the speakers at the Milken Institute Global Conference 2013,[49] delivered the keynote Andrew C. Novick Memorial Lecture at the Ninth International Kidney Cancer Symposium,[50] and regularly presents at the Annual J.P. Morgan Healthcare Conference.[51] It was announced that Belldegrun will present at the 34th Annual J.P. Morgan Healthcare Conference in January 2016.[52]

gollark: They generally just take one outdated kernel version, patch in the code they need, ship it, and then never update it, instead of "upstreaming" the drivers so they'll be incorporated in the official Linux source code.
gollark: You know how I said that companies were obligated to release the source code to the kernel on their device? Some just blatantly ignore that (*cough*MediaTek*cough*). And when it *is* there, it's actually quite bad.
gollark: It's actually worse than *just* that though, because of course.
gollark: There are some other !!FUN!! issues here which I think organizations like the FSF have spent some time considering. Consider something like Android. Android is in fact open source, and the GPL obligates companies to release the source code to modified kernels and such; in theory, you can download the Android repos and device-specific ones, compile it, and flash it to your device. How cool and good™!Unfortunately, it doesn't actually work this way. Not only is Android a horrible multiple-tens-of-gigabytes monolith which takes ages to compile (due to the monolithic system image design), but for "security" some devices won't actually let you unlock the bootloader and flash your image.
gollark: The big one *now* is SaaS, where you don't get the software *at all* but remote access to some on their servers.

References
  1. Bartholomew, Dana (23 March 2018). "Professor as Entrepreneur: UCLA's Belldegrun on to Next Biopharma Enterprise". Los Angeles Business Journal. Retrieved 10 May 2020.
  2. "Curriculum Vitae", InfoFAQ, July 2007. Retrieved on 22 June 2013.
  3. "Dr. Arie S. Belldegrun, MD, FACS Joins Two River Group Holdings as Chairman and Partner". Reuters. 29 April 2008. Retrieved 25 June 2013.
  4. "Arie Belldegrun, MD" Archived July 15, 2013, at the Wayback Machine, UCLA Health. Retrieved on 25 June 2013.
  5. "Arie Belldegrun, M.D.", David Geffen School of Medicine. Retrieved on 25 June 2013.
  6. "Arie Belldegrun, M.D.", USRF. Retrieved on 23 June 2013.
  7. "Advisory Board", Penn LSM. Retrieved on 28 August 2013.
  8. Moster, Roxanne & Champeau, Rachel (27 November 2007). "UCLA scientists' biotech firm to be acquired by pharmaceutical corp." Archived 2013-11-13 at the Wayback Machine. UCLA Newsroom. Retrieved 25 June 2013.
  9. "Board of Directors" Archived June 30, 2013, at the Wayback Machine, Nile Therapeutics. Retrieved on 25 June 2013.
  10. "Company Overview of Two River Group Holdings, LLC", Businessweek. Retrieved on 26 June 2013.
  11. "Johnson & Johnson Completes Acquisition of Cougar Biotechnology" Archived November 1, 2012, at the Wayback Machine. Cougar Biotechnology. 10 July 2009. Retrieved 25 June 2013.
  12. "Board of Directors", Arno Therapeutics. Retrieved on 25 June 2013.
  13. "About Kite Pharma" Archived January 21, 2015, at the Wayback Machine. Kite Pharma. Retrieved 21 January 2015.
  14. http://uk.reuters.com/article/us-kite-pharma-m-a-gilead-sciences-idUKKCN1B810Y
  15. "Growth-hungry Gilead finally pivots from flagging hep C with $12B Kite buy". fiercepharma.com. 2017-08-28. Retrieved 2017-08-29.
  16. "Gilead | Investors | News Release". investors.gilead.com. Retrieved 2017-10-29.
  17. "Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy". Gilead. 18 October 2017. Retrieved 24 December 2017.
  18. Stendahl, Max (15 December 2017). "Vida Ventures, Boston’s newest healthcare VC firm, unveils $255M fund". Boston Business Journal. Retrieved 24 December 2017.
  19. Densford, Fink (18 December 2017). "Boston VC firm Vida Ventures unveils $255m healthcare fund". Mass Device. Retrieved 24 December 2017.
  20. "About Us - Vida Ventures". Vida Ventures. Retrieved on 15 June 2018.
  21. "Vida Ventures Unveils Next-Generation Life Sciences Venture Firm with $295 Million Under Management and an Investment in Allogene Therapeutics". BusinessWire. 3 April 2018. Retrieved 3 April 2018.
  22. "Portfolio - Vida Ventures". Vida Ventures. Retrieved 16 July 2019.
  23. "Allogene Therapeutics". Allogene Therapeutics. Retrieved on 3 April 2018.
  24. Herper, Matthew (3 April 2018). "They're Back! After Selling Kite, Belldegrun And Chang Seek To Change Cancer Treatment Again". Forbes. Retrieved on 3 April 2018.
  25. Carroll, John (3 April 2018). "Arie Belldegrun raises $300M, grabs Pfizer’s allogeneic CAR-T portfolio and launches a groundbreaking drive to commercialization". Endpoint News. Retrieved on 3 April 2018.
  26. Taylor, Phil (6 September 2018). "Allogene raises another $120M for off-the-shelf CAR-T programs". FierceBiotech. Retrieved 12 October 2018.
  27. Nisen, Max (11 October 2018). "Allogene’s Monster Biotech IPO Defies Market Rout". Bloomberg. Retrieved 12 October 2018.
  28. Mukherjee, Sy (11 October 2018). "Why Cancer Biotech Allogene Just Scored an Eye Popping $324 Million IPO" Fortune. Retrieved 12 October 2018.
  29. McDonald, Michael & Katz, Lily (16 July 2019). "Doctor Who Sold $12 Billion Drug Firm Eyes Biotech Property". Bloomberg. Retrieved 16 July 2019.
  30. "Tishman Speyer and Bellco Capital Launch Breakthrough Properties, a First-of-Its-Kind Global Life Sciences Real Estate Platform". BusinessWire. 16 July 2019. Retrieved 16 July 2019.
  31. "Vida Ventures Closes $600 Million Vida II Fund to Support Life Science Innovation ". BusinessWire. 1 August 2019. Retrieved 18 October 2019.
  32. "Arie Belldegrun, M.D.", USRF. Retrieved on 23 June 2013.
  33. "Architecture Project Entries 2003", AIANY, 2003. Retrieved on 23 June 2013.
  34. Melin, Anders & Chen, Caroline (11 June 2015). "Biotech CEOs among highest-paid US execs". Telegram.com. Retrieved 7 July 2015.
  35. "Hollywood's Top Doctors 2015: Best Urologists in Los Angeles". The Hollywood Reporter. 27 August 2015. Retrieved 15 June 2018.
  36. "246 מיליארד דולר: השווי של 500 עשירי ישראל נחשף" (in Hebrew). TheMarker. Retrieved 27 July 2020.
  37. "$1M Lifetime Donors to the School of Arts and Sciences". University of Pennsylvania. 30 June 2012. Retrieved 17 June 2016.
  38. "Smoke | LACMA Collections". LACMA. Retrieved 17 June 2016.
  39. "Tony Smith's monumental sculpture 'Smoke' will not disappear from LACMA; multimillion-dollar purchase finalized". Los Angeles Times. 18 June 2010. Retrieved 17 June 2016.
  40. "LA 500: Arie Belldegrun". Los Angeles Business Journal. 11 August 2017. Retrieved 25 June 2019.
  41. "Arie Belldegrun, MD". Los Angeles Business Journal. 30 July 2018. Retrieved 25 June 2019.
  42. "Arie Belldegrun". Los Angeles Business Journal. 20 May 2019. Retrieved 14 January 2020.
  43. "LA500 2020: Health Care". Los Angeles Business Journal. 25 May 2020. Retrieved 25 May 2020.
  44. Lawrence, Carol (23 March 2018). "Laurels for Leaders: Aecom Boss Burke Highlights Class of Annual Honorees". Los Angeles Business Journal. Retrieved on 3 April 2018.
  45. "CEO Today USA Awards 2017". CEO Today. 2018. Retrieved 22 February 2018.
  46. "UroGen Pharma’s Chairman, Arie Belldegrun, MD, FACS to Receive EY 2018 Master Entrepreneur Award". GlobeNewswire. 13 June 2018. Retrieved 15 June 2018.
  47. "Nile Therapeutics Appoints Arie S. Belldegrun, M.D., to Board of Directors". Reuters. Retrieved 13 November 2013.
  48. "US HIFU Appoints Arie Belldegrun, M.D. to Board of Directors". Reuters. Retrieved 13 November 2013.
  49. "Global Conference 2013" Archived November 13, 2013, at the Wayback Machine. Milken Institute. Retrieved 13 November 2013.
  50. "Medical Symposia Keynote Addresses" Archived November 13, 2013, at the Wayback Machine. Kidney Cancer Association. Retrieved 13 November 2013.
  51. "Kite Pharma to Present at the 32nd Annual J.P. Morgan Healthcare Conference". BizJournals (Charlotte). 7 January 2014. Retrieved 26 May 2014.
  52. "Kite Pharma to Present at the 34th Annual J.P. Morgan Healthcare Conference". NASDAQ. 6 January 2016. Retrieved 6 January 2016.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.